Journal
FRONTIERS IN PHARMACOLOGY
Volume 13, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fphar.2022.859755
Keywords
doxorubicin; apoptosis; oxidative stress; inflammation; Naringin; ECHS1
Categories
Funding
- Natural Science Foundation of Liaoning Province [2019-ZD-0652]
- Scientific research project of Liaoning Provincial Department of Education [LJKZ0857]
- Dalian Medical Science Research Project [1912006]
- Natural Science Foundation of China [82070380]
- Youth Science and Technology Star Project of Dalian [2020RQ073]
Ask authors/readers for more resources
The study found that Naringin can prevent DOX-related cardiac injury and inhibit oxidative stress, inflammation, and apoptosis in the heart both in vivo and in vitro. These findings suggest that Naringin may serve as a novel approach to prevent cardiac toxicity induced by anthracycline drugs.
Doxorubicin (DOX) leads to myocardial cell damage and irreversible heart failure, which limits the clinical application of DOX. Naringin has biological functions of inhibiting inflammation, oxidative stress and apoptosis. Our aim was to investigate whether Naringin could prevent DOX-related cardiotoxicity in mice. Naringin was administered by gavage and mice were intraperitoneally injected with doxorubicin (1 mg/kg/day) for 15 days. H&E, Masson, TUNEL and others experiments were examined. NRVMs and H9C2 cells were treated with Naringin and DOX in vitro. Using IF, ELISA and Western Blot to detect the effect of Naringin and ECHS1 on cells. The results showed that Naringin could prevent DOX related cardiac injury, inhibit cardiac oxidative stress, inflammation and apoptosis in vivo and in vitro. Inhibition of ECHS1 could interfere the effect of Naringin on DOX-induced myocardial injury. Naringin may provide a new cardiac protective tool for preventing the cardiotoxicity of anthracycline drugs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available